Empagliflozin alias New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 23, 2020 /PRNewswire/ — Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance® (empagliflozin) reduced the risk of adverse…